Trial Profile
A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150 mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jul 2023
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Roche
- 07 Dec 2008 Results presented at IOF World Congress on Osteoporosis 2008.
- 14 Oct 2008 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
- 12 Sep 2008 Results presented at ASBMR 2008.